Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
David Mutch, Athina Voulgari, Xian Chen, William H. Bradley, Ana Oaknin, José Alejandro Perez Fidalgo, Fernando Galvez Montosa, Antonio Casado Herraez, Robert W. Holloway, Matthew A. Powell, Malgorzata Nowicka, Gabriele Schaefer, Mark Merchant, Yibing Yan
Dive into the research topics of 'Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer'. Together they form a unique fingerprint.